TearClear Announces Positive Topline Results from CLEAR Phase 3 Study for the Treatment of Glaucoma with TC-002 (latanoprost ophthalmic solution 0.005%)
29 sept. 2022 13h00 HE
|
TearClear Corp.
Successfully met the primary and all secondary endpoints On track for New Drug Application (NDA) filing, with the FDA in Q1 2023 TC-002 is the first of four proprietary glaucoma drugs in the...
TearClear announces the successful initiation of its TC-002 Latanoprost Ophthalmic Solution Phase 3 trial
07 févr. 2022 05h00 HE
|
TearClear Corp.
BOSTON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- TearClear, a late clinical stage ophthalmic pharmaceutical company, is pleased to announce the TC-002 Phase 3 trial has been successfully initiated....
TearClear Files Investigational New Drug (IND) Application to Begin its Clinical Trial for TC-002 Latanoprost Ophthalmic Solution, 0.005%
08 sept. 2021 09h52 HE
|
TearClear Corp.
BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- TearClear, a late clinical stage ophthalmic pharmaceutical company, has filed an Investigational New Drug (IND) application to conduct a registrational...
TearClear Moving Toward Clinical Trials and Strengthening Leadership Team
16 mars 2021 07h28 HE
|
TearClear Corp.
BOSTON, March 16, 2021 (GLOBE NEWSWIRE) -- TearClear continues to make progress on the development of its first-in-class platform of preservative-free topical medications. With a successful Pre-IND...
TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma
01 déc. 2020 06h00 HE
|
TearClear Corp.
BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- TearClear, an emerging ophthalmic pharmaceutical company, today announced successful completion of pre-IND (Investigational New Drug) meeting with the U.S....
TearClear Appoints Robert Bailey to Board of Directors
29 sept. 2020 06h00 HE
|
TearClear Corp.
BOSTON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- TearClear announces the appointment of industry veteran Robert Bailey to the company’s Board of Directors. Mr. Bailey brings over two decades of leadership...
TearClear Raises $22 Million to Advance Multiple Clinical Programs in Development
11 août 2020 07h00 HE
|
TearClear Corp.
BOSTON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- TearClear has raised $22M in a Series B funding round. The investment will be used to advance multiple clinical programs in development, with two lead...
TearClear appoints Dr. Amir Shojaei Chief Development Officer
20 mai 2020 07h00 HE
|
TearClear Corp.
BOSTON, May 20, 2020 (GLOBE NEWSWIRE) -- TearClear Corp., an emerging Ophthalmic Pharmaceutical Company, has announced the appointment of Amir Shojaei, Pharm.D., Ph.D., as Chief Development Officer,...
TearClear appoints Robert J. Dempsey Chief Executive Officer
16 avr. 2020 07h30 HE
|
TearClear Corp.
BOSTON, April 16, 2020 (GLOBE NEWSWIRE) -- TearClear, a global Ophthalmic Pharmaceutical Company, today announced the appointment of Robert J. Dempsey as Chief Executive Officer. TearClear is the...
TearClear Appoints Chief Scientific and Innovation Officer
29 mai 2019 08h00 HE
|
TearClear Corp.
Industry Leader Srini Venkatesh, PhD, to drive TearClear’s scientific and R&D strategy Supports the next phase of development for its disruptive ophthalmic pharmaceutical platform ORANGE...